Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease) in Spain: A Systematic Review

Overview

Journal Adv Ther

Date 2023 Mar 17

PMID 36928496

Authors

Manuel Barreiro-de Acosta

Alberto Molero

Esther Artime

Silvia Diaz-Cerezo

Luis Lizan

Hector David de Paz

Maria Dolores Martin-Arranz

Affiliations

Soon will be listed here.

Abstract

Introduction: This study describes the epidemiological, clinical, patient-reported and economic burden of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), in Spain.

Methods: A systematic review was performed of observational studies reporting the epidemiological, clinical, patient-reported and economic burden of IBD in the Spanish population, from 2011 to 2021. Original articles and conference abstracts published in English or Spanish were eligible.

Results: A total of 45 publications were included in the review. The incidence of IBD in adults ranged from 9.6 to 44.3 per 100,000 inhabitants (4.6 to 18.5 for CD and 3.4 to 26.5 for UC). The incidence increased between 1.5- and twofold from 2000 to 2016 (regionally). Up to 6.0% (CD) and 3.0% (UC) IBD-associated mortality was reported. Disease onset predominantly occurs between 30 and 40 years (more delayed for UC than CD). Most frequently reported gastrointestinal manifestations are rectal bleeding in UC and weight loss in CD. Extraintestinal manifestations (EIM) have been described in up to 47.4% of patients with CD and 48.1% of patients with UC. Psychiatric comorbidities were frequently reported in both CD and UC (depression up to 20% and anxiety up to 11%). Reduced health-related quality of life (HRQoL) compared to the general population was reported. Significant symptomatology was associated with high levels of anxiety, depression, stress and lower HRQoL. Main healthcare resources reported were emergency department visits (24.0%), hospitalization (14.7%), surgery (up to 11%) and use of biologics (up to 60%), especially in CD. Direct and indirect annual costs per patient with UC were €1754.1 and €399.3, respectively.

Conclusion: Patients with CD and UC present a high disease burden which negatively impacts their HRQoL, leading to elevated use of resources.

Citing Articles

Monotropein inhibits epithelial-mesenchymal transition in chronic colitis via the mTOR/P70S6K pathway.

Chen Y, Liu J, Zhong S, Zhang T, Yuan J, Zhang J Front Pharmacol. 2025; 16:1536091.

PMID: 40041493 PMC: 11876156. DOI: 10.3389/fphar.2025.1536091.

The Role of Maternal and Early-Life Diet in Inflammatory Bowel Disease.

Karaivazoglou K, Triantos C, Aggeletopoulou I Nutrients. 2025; 16(24.

PMID: 39770913 PMC: 11677091. DOI: 10.3390/nu16244292.

Identification and Validation of Biomarkers to Predict Early Diagnosis of Inflammatory Bowel Disease and Its Progression to Colorectal Cancer.

Khan F, Abdulla N, du Plessis T, Karlsson K, Barrow P, Bebington B Biochem Genet. 2024; .

PMID: 39325241 DOI: 10.1007/s10528-024-10917-z.

Causal association between inflammatory bowel disease and acute pancreatitis: a two-sample bidirectional mendelian randomization study.

Zhang C, Fan X, Li Z, Hu Z, He C, Wang S Front Genet. 2024; 15:1324893.

PMID: 39205942 PMC: 11349681. DOI: 10.3389/fgene.2024.1324893.

Exposure to polyethylene microplastics exacerbate inflammatory bowel disease tightly associated with intestinal gut microflora.

Ghosal S, Bag S, Rao S, Bhowmik S RSC Adv. 2024; 14(35):25130-25148.

PMID: 39139248 PMC: 11320195. DOI: 10.1039/d4ra04544k.

References

Panaccione R . Mechanisms of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2014; 9(8):529-32. PMC: 3980998. View

Zhou N, Chen W, Chen S, Xu C, Li Y . Inflammatory bowel disease unclassified. J Zhejiang Univ Sci B. 2011; 12(4):280-6. PMC: 3072591. DOI: 10.1631/jzus.B1000172. View

Vavricka S, Schoepfer A, Scharl M, Lakatos P, Navarini A, Rogler G . Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015; 21(8):1982-92. PMC: 4511685. DOI: 10.1097/MIB.0000000000000392. View

Molodecky N, Kaplan G . Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2010; 6(5):339-46. PMC: 2886488. View

Neuman M, Nanau R . Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res. 2012; 160(1):29-44. DOI: 10.1016/j.trsl.2011.09.001. View

Lamb C, Kennedy N, Raine T, Hendy P, Smith P, Limdi J . British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019; 68(Suppl 3):s1-s106. PMC: 6872448. DOI: 10.1136/gutjnl-2019-318484. View

Kirchgesner J, Lemaitre M, Rudnichi A, Racine A, Zureik M, Carbonnel F . Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014. Aliment Pharmacol Ther. 2016; 45(1):37-49. DOI: 10.1111/apt.13835. View

Flamant M, Roblin X . Inflammatory bowel disease: towards a personalized medicine. Therap Adv Gastroenterol. 2018; 11:1756283X17745029. PMC: 5784543. DOI: 10.1177/1756283X17745029. View

Beard J, Franco D, Click B . The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care. Curr Gastroenterol Rep. 2020; 22(2):6. DOI: 10.1007/s11894-020-0744-z. View

10.

Burisch J, Jess T, Martinato M, Lakatos P . The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013; 7(4):322-37. DOI: 10.1016/j.crohns.2013.01.010. View

11.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

12.

Algaba A, Guerra I, Castano A, de la Poza G, Castellano V, Lopez M . Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease. World J Gastroenterol. 2014; 19(48):9359-65. PMC: 3882409. DOI: 10.3748/wjg.v19.i48.9359. View

13.

Brunet E, Roig-Ramos C, Vela E, Cleries M, Melcarne L, Villoria A . Prevalence, incidence and mortality of inflammatory bowel disease in Catalonia. A population-based analysis. Ann Med. 2018; 50(7):613-619. DOI: 10.1080/07853890.2018.1523550. View

14.

Burisch J . Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. Dan Med J. 2014; 61(1):B4778. View

15.

Benallal D, Guerra Veloz M, Arguelles-Arias F, Manuel Benitez J, Perea Amarillo R, Iglesias E . Evolution of the incidence of inflammatory bowel disease in Southern Spain. Rev Esp Enferm Dig. 2017; 109(11):757-760. DOI: 10.17235/reed.2017.4739/2016. View

16.

Fernandez A, Hernandez V, Martinez-Ares D, Sanroman L, de Castro M, Pineda J . Incidence and phenotype at diagnosis of inflammatory bowel disease. Results in Spain of the EpiCom study. Gastroenterol Hepatol. 2015; 38(9):534-40. DOI: 10.1016/j.gastrohep.2015.03.001. View

17.

Lucendo A, Hervias D, Roncero O, Lorente R, Bouhmidi A, Angueira T . Epidemiology and temporal trends (2000-2012) of inflammatory bowel disease in adult patients in a central region of Spain. Eur J Gastroenterol Hepatol. 2014; 26(12):1399-407. DOI: 10.1097/MEG.0000000000000226. View

18.

Marin-Jimenez I, Saro C, Diaz V, Barreiro-de Acosta M, Gomez-Garcia M, Gutierrez Casbas A . Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE study). Drugs Context. 2018; 7:212505. PMC: 5842877. DOI: 10.7573/dic.212505. View

19.

Martin-de-Carpi J, Rodriguez A, Ramos E, Jimenez S, Martinez-Gomez M, Medina E . Increasing incidence of pediatric inflammatory bowel disease in Spain (1996-2009): the SPIRIT Registry. Inflamm Bowel Dis. 2012; 19(1):73-80. DOI: 10.1002/ibd.22980. View

20.

Martin-de-Carpi J, Rodriguez A, Ramos E, Jimenez S, Martinez-Gomez M, Medina E . The complete picture of changing pediatric inflammatory bowel disease incidence in Spain in 25 years (1985-2009): the EXPERIENCE registry. J Crohns Colitis. 2014; 8(8):763-9. DOI: 10.1016/j.crohns.2014.01.005. View